新辅助化疗后手术和同期放化疗在ⅡB期子宫颈癌中的临床应用价值  

Clinical Value of Surgery after Neoadjuvant Chemotherapy and Concurrent Chemoradiotherapy in StageⅡB Cervical Cancer

作　　者：程细云 张秀英 申昌梅 吴修洪 余瑛 廖振蓉 王琪 黄晶 CHENG Xiyun;ZHANG Xiuying;SHEN Changmei;WU Xiuhong;YU Ying;LIAO Zhenrong;WANG Qi;HUANG Jing(Ganzhou Cancer Hospital,Ganzhou 341000,China;不详)

机构地区：[1]江西省赣州市肿瘤医院,江西赣州341000 [2]江西省赣州市赣县第二医院

出　　处：《中国医学创新》2021年第17期131-134,共4页Medical Innovation of China

基　　金：赣州市指导性科技计划项目(GZ2019ZSF262)。

摘　　要：目的:探究新辅助化疗后手术和同期放化疗在ⅡB期子宫颈癌中的临床应用价值。方法:选取2017年1月-2018年1月在本院住院治疗的60例子宫颈癌患者为研究对象。按照随机数字表法将患者分为研究组30例和对照组30例。两组均行手术治疗,研究组患者术前行新辅助化疗,术后行同期放化疗治疗,对照组术后给予同期放化疗治疗。比较两组患者的手术指标和1、3年生存情况,临床疗效以及不良反应发生情况。结果:两组患者手术时间比较,差异无统计学意义(P>0.05);研究组术中出血量少于对照组,差异有统计学意义(P<0.05)。研究组有效率为66.67%,高于对照组的40.00%,差异有统计学意义(P<0.05)。两组患者1年生存率比较,差异无统计学意义(P>0.05);研究组3年生存率高于对照组,差异有统计学意义(P<0.05)。同期放化疗后6个月,研究组bFSH水平低于对照组,bE2水平高于对照组,差异均有统计学意义(P<0.05)。研究组不良反应发生率为20.00%,低于对照组的46.67%,差异有统计学意义(P<0.05)。结论:相比术后同期放化疗,新辅助化疗后手术在ⅡB期子宫颈癌的治疗中,可提高临床治疗效果和生存率,同时降低不良反应发生率,有效保护卵巢功能,具有临床进一步推广应用价值。Objective:To explore the clinical value of surgery after neoadjuvant chemotherapy and concurrent chemoradiotherapy in stageⅡB cervical cancer.Method:A total of 60 cervical cancer patients hospitalized in our hospital from January 2017 to January 2018 were selected as the research objects.According to the random number table method,the patients were divided into study group(30 cases)and control group(30 cases).Both groups received surgical treatment,patients in the study group received neoadjuvant chemotherapy before surgery,and concurrent chemoradiotherapy after surgery,while patients in the control group received concurrent chemoradiotherapy after surgery.The surgical indexes,1-year and 3-year survival,clinical efficacy and the incidence of adverse reactions in two groups were compared.Result:There was no significant difference in surgery time between two groups(P>0.05).The amount of during surgery blood loss in the study group was less than that in the control group,the difference was statistically significant(P<0.05).The effective rate of the study group was 66.67%,higher than 40.00%of the control group,the difference was statistically significant(P<0.05).There was no significant difference in 1-year survival rate between two groups(P>0.05).The 3-year survival rate in the study group was higher than that in the control group,the difference was statistically significant(P<0.05).Six months after concurrent chemoradiotherapy,the level of bFSH in the study group was lower than that in the control group,while the level of bE2 was higher than that in the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the study group was 20.00%,which was lower than 46.67%in the control group,the difference was statistically significant(P<0.05).Conclusion:Compared with postoperative concurrent chemoradiotherapy,neoadjuvant chemotherapy after surgery in the treatment of stageⅡB cervical cancer,can improve the clinical treatment effect and survial rate,while reducing the in

关 键 词：ⅡB期子宫颈癌 新辅助化疗 同期放化疗 

分 类 号：R737.33[医药卫生—肿瘤]